Pioneering the development
of engineered IgM antibodies
NEWS
IGM Announces Pricing of Upsized $200 million Public Offering
IGM Announces Proposed Public Offering
PRESENTATIONS & PUBLICATIONS
Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity
AACR Annual Meeting 2021 Virtual – April 10-15, 2021 Session: Therapeutic Mechanisms of Novel Anticancer Agent, Abstract No. 52
Clinical Challenges and Engineering Solutions in Cancer Immunotherapy: What Do We Need Now?
Nature Research Webcast: Immuno-oncology: IgG and Beyond – April 6, 2021
Potent Anti-Tumor Activity of IGM-8444, an Agonist DR5 IgM, Displays Strong Synergy with Chemotherapy and Inducers of Apoptosis
Festival of Biologics USA – March 29 to April 1, 2021
Delivery of IL-15 to PD-L1 Expressing Tumors with an Anti-PD-L1 IgM
Cytokine-Based Cancer Immunotherapies Summit – March 24-25, 2021
In the Media: Nature Biotechnology – Bispecific Antibodies Poised to Deliver Wave of Cancer Therapies
Citation: Sheridan, C. Bispecific antibodies poised to deliver wave of cancer therapies. Nat Biotechnol 39, 251–254 (2021) https://doi.org/10.1038/s41587-021-00850-6
Abstract: Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity
AACR Annual Meeting – April 10-15, 2021 Regular abstract titles, authors, and text released – March 10, 2021
Engineering on a Natural Multivalent Antibody Platform: Solving Clinical Challenges with Experimental IgM Therapeutics
ESMO Targeted Anticancer Therapies Virtual Congress 2021 – March 1-2, 2021 Session: Multispecific Biological Constructs – March 2, 2021
Endogenous Immunity, Synthetic Immunity and Engineering IgM Therapeutics
Immuno-Oncology 360° – February 23-26, 2021 Bispecifics Plenary Session – February 26, 2021
At the Intersection of Science and Engineering: Novel Platform Approach to Immunotherapy with IGM-2323
ESMO Immuno-Oncology Virtual Congress 2020 – December 9-12, 2020 Educational Session: Novel Immunotherapeutic Platforms – December 11, 2020
The Anti-Tumor Activity of IGM-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML
62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2020 Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents Abstract Number: 2093, December 6, 2020